Milk-based dietary supplement produces significant results in two placebo-controlled trials . 牛奶为基础的膳食补充剂产生显着的成果在两个安慰剂对照试验 。

Two new clinical trials presented by Calpis Co., Ltd. at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition (ASH 2008) show that the milk-derived dietary supplement AmealPeptide® reduces blood pressure in hypertensive patients.两个新的临床试验由calpis有限公司，在美国高血压学会（灰） 20 -第三次年度科学会议和博览会（灰分2008年）表明，该牛奶衍生的膳食补充剂amealpeptide ®降低血压的高血压患者。 The studies, called AHEAD (Achieve Hypertension Efficacy with AmealPeptide® Dietary Supplement ) II, and the PROBE (A Prospective, Two-phase Randomized, Open-Label, Blinded End-Point) Dose Response Study confirmed the safety and efficacy of AmealPeptide® for patients with Stage I and Stage II hypertension.研究，所谓的未来（达到高血压的疗效与amealpeptide ®膳食补充剂） ，第二和探头（准，两相随机，开放标签，利欲熏心的终结点）的剂量响应研究证实了的安全性和疗效amealpeptide ®为病人与I阶段和第二阶段的高血压。

AmealPeptide® is derived from the milk protein casein and consists of two tripeptides - Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP) - that have been shown to have characteristics of angiotensin converting enzyme (ACE) inhibitors . amealpeptide ®是来自牛奶蛋白酪连续两个tripeptides -缬氨酸-脯氨酸-脯氨酸（ v pp）和异亮氨酸-脯氨酸-脯氨酸（ I PP）实现-这已被证明有特色的血管紧张素转换酶（ A C E）抑制剂。 These peptide sequences exist naturally in casein.这些多肽序列的存在，自然在酪蛋白。 However, they are not released in the gut by the action of digestive enzymes.然而，他们没有公布在肠道所采取的行动，消化酶活性。 They are released by propriety fermentation and enzymatic processes developed by Calpis Co., Ltd.他们所发表的是否恰当，发酵和酶催化过程的开发calpis有限公司

The AHEAD II study found that the milk-based product produced a mean drop in daytime, ambulatory systolic blood pressure of 3.6 mmHg for the active group after 6 weeks of treatment.在未来的二，研究发现，牛奶为基础的产品生产，平均下降，白天，日间收缩压为3.6毫米汞柱，为积极组6周后的治疗。 The change was both statistically and clinically significant.这项改变是双方在统计和临床意义。 According to JNC 7 (The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure), just a 2 mmHg reduction in systolic blood pressure results in a 6% reduction in mortality due to stroke and a 4% reduction in mortality due to coronary heart disease (CHD).据联合谈判委员会第7 （第七次报告联合全国委员会关于预防，检测，评估和治疗血压高的压力） ，只是一个2毫米汞柱减少，收缩压结果在6 ％ ，减少了死亡率，由于中风和一四％ ，减少了死亡率，由于冠心病（ CHD ） 。

Results of the PROBE study showed AmealPeptide® to have a dose dependent blood pressure lowering trend and a reduction of daytime ambulatory blood pressure of 7.6 mmHg (± 8.7) in the 75 mg a day group and also a significant reduction in 24-hr systolic blood pressure in the same group of 6.2 mmHg (± 8.4) from the baseline after 8 weeks of treatment.结果探针研究表明， amealpeptide ®有一个剂量依赖性血压降低的趋势，并减少日间动态血压的压力7.6毫米汞柱（ ± 8.7 ）在75毫克， 1天组，也显着减少，在24小时收缩压压力在同一组的6.2毫米汞柱（ ± 8.4 ）从基线后8周的治疗。 A lower dose of 5 mg a day of AmealPeptide® also showed blood pressure lowering effect.较低的剂量为5毫克，一天的amealpeptide ®还表明，血压降低的效果。

“It’s very exciting to see blood pressure reductions achieved by the food derived substance, AmealPeptide®” stated Joel Neutel, MD, Associate Clinical Professor of Medicine at the University of California, Irvine and a specialist in clinical hypertension of the American Society of Hypertension. “这是令人十分振奋地看到，血压降低所取得的由食物产生的物质， amealpeptide ® ”声明的Joel neutel ，医学博士，副临床的医学教授在加州大学尔湾分校和专家在临床高血压的美国社会高血压。 “With hypertension and prehypertension on the rise, physicians and patients need as many effective tools as possible for the management of this condition,” he concluded. “与高血压prehypertension在上升，医生和患者所需要的许多有效的工具，尽可能为管理这个条件， ”他的结论。

The AHEAD II study enrolled 81 newly diagnosed stage I and stage II hypertensives.在未来的二，研究参加81初诊I阶段和第二阶段的高血压患者。 All subjects had a mean daytime systolic blood pressure between 140 mmHg and 179 mmHg at the start of the trial.所有受试者平均日间收缩压一百四十毫米汞柱之间和179毫米汞柱，在审判开始。 Fifty-two received 75 mg of AmealPeptide® twice a day for 6 weeks, while 29 received a placebo. 52收到75毫克的amealpeptide ®一天两次为六周，而29日收到了安慰剂。 The PROBE study enrolled 59 diagnosed stage I and stage II hypertensives who were not taking any antihypertensive medications or who were uncontrolled on antihypertensive therapy.探头研究参加59诊断为I阶段和第二阶段的高血压病患者谁不采取任何抗高血压药物治疗或谁被不受控制地对降压治疗。 All subjects had a mean seated systolic blood pressure between 150 mmHg and 179 mmHg and a mean daytime systolic blood pressure between 140 mmHg and 179 mmHg at the start of the trial.所有科目的了的意思坐下收缩压150毫米汞柱和179毫米汞柱和平均日间收缩压一百四十毫米汞柱之间和179毫米汞柱，在审判开始。 All enrolled received AmealPeptide® (5mg, 15mg, 50mg, 75mg a day or 75mg twice a day) or placebo.所有登记收到amealpeptide ® （ 5毫克， 15 mg ， 50毫克， 1天75 mg或75 mg一天两次）或安慰剂。

"Calpis takes pride in conducting research that holds up under serious scientific scrutiny," said Craig Tillman, Vice President of Sales & Marketing, Calpis USA, Inc. "This new data confirms that AmealPeptide® can make a difference in those with elevated blood pressure." “ calpis引以自豪的进行研究，拥有下严重的科学审议，说： ”克雷格迪尔曼，副总裁销售及市场推广， calpis美国公司： “这个新的数据证实， amealpeptide ®可以作出不同的那些与血压升高“ 。

The AHEAD II and PROBE data builds on more than 11 previous Japanese placebo-controlled clinical studies showing that AmealPeptide® lowers blood pressure in hypertensives and prehypertensives without producing the side effects that can be associated with drug therapy (Courtesy of EurekAlert!, a service of AAAS).在未来的第二和探针的数据建立在1100多日本历届安慰剂对照的临床研究显示， amealpeptide ®降低血压，高血压病患者和prehypertensives没有产生副作用，可与药物疗法（礼貌eurekalert ！ ，服务科促会） 。